Physician profile
Joy Murphy
NPI 1851321103
$6,833.36
in general payments reported to CMS, 2019-2025
30 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,887 · 2022: $2,276 · 2023: $1,500 · 2024: $727 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,190.36 | 2021-2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $1,113.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,103.17 | 2021-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $757.64 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $619.85 | 2021-2025 | |
| Nevro Corp. | $287.76 | 2022-2024 | Senza |
| Lilly USA, LLC | $262.03 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $229.90 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $181.97 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $145.79 | 2023-2025 | Farxiga, Airsupra |
| Recordati_rare_diseases_inc. | $125.95 | 2021-2023 | Signifor Lar, Isturisa |
| Corcept Therapeutics | $111.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $91.57 | 2024 | |
| Medtronic, INC. | $82.27 | 2021-2023 | Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $79.94 | 2021-2023 | Gvoke Hypopen |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $62.82 | 2021-2023 | Tirosint, Licart |
| Eusa Pharma (US) LLC | $52.29 | 2022 | |
| Embecta Corp. | $52.02 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Exact Sciences Corporation | $45.64 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.48 | 2021-2022 | |
| Becton, Dickinson and Company | $32.54 | 2022 | |
| Recor Medical INC | $30.75 | 2024 | Paradise Renal Denervation System |
| Ultragenyx Pharmaceutical INC. | $21.10 | 2021 | |
| Radius Health, INC. | $17.81 | 2024 | Tymlos |
| Amphastar Pharmaceuticals, INC. | $17.33 | 2024 | |
| Alexion Pharmaceuticals, INC. | $17.25 | 2023 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.81 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $16.45 | 2024 | |
| Glaxosmithkline, LLC. | $16.20 | 2023 | Shingrix, Arexvy |
| Pfizer INC. | $15.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.